Intraocular concentrations of gatifloxacin and moxifloxacin in the anterior chamber via diffusion through the cornea using collagen shields

Cornea

Volumn 25, Issue 2, 2006, Pages 209-213

  Kleinmann, Guy ^a   Larson, Scott ^a   Neuhann, Irmingard M ^a   Hunold, Anne C ^a   LeBoyer, Russell ^a   Hickman, Scott ^a   Mamalis, Nick ^a   Olson, Randall J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Collagen shields; Gatifloxacin; Intraocular concentration; Moxifloxacin

Indexed keywords

COLLAGEN; GATIFLOXACIN; MOXIFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; COLLAGEN SHIELD; CONTROLLED STUDY; CORNEA; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG PENETRATION; DRUG TISSUE LEVEL; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; AQUEOUS HUMOR; AZA COMPOUNDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLLAGEN; CORNEA; DIFFUSION; DRUG CARRIERS; FLUOROQUINOLONES; FOLLOW-UP STUDIES; MALE; OPHTHALMIC SOLUTIONS; QUINOLINES; RABBITS;

EID: 33644834187     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000170689.75207.5e     Document Type: Article

References (24)

1. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology. 2002;109: 13-26.
2. Schmitz S, Dick HB, Krummenauer F, et al. Endophthalmitis in cataract surgery: results of a German survey. Ophthalmology. 1999;106:1869-1877.
3. Lehmann OJ, Roberts CJ, Ikram K. Association between nonadministration of subconjuctival ceferoxime and postoperative endophthalmitis. J Cataract Refract Surg. 1997;23:889-893.
4. Montan PG, Wejde G, Koranyi G. Prophylactic intracameral cefuroxime: efficacy in preventing endophthalmitis after cataract surgery. J Cataract Refract Surg. 2002;28:977-981.
5. Wallin T, Parker J, Jin Y, et al. A cohort study of 27 cases of endophthalmitis at a single institution. J Cataract Refract Surg. 2005;31: 735-741.
6. Smith A, Pennefather PM, Kaye SB, et al. Fluoroquinolones: place in ocular therapy. Drugs. 2001;61:747-761.
7. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497-1502.
8. Chaudhry NA, Flynn HW, Murray TG, et al. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999;128:509-510.
9. Goldstein MH, Kowalski RP, Gordon J. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999; 106:1313-1318.
10. Watanabe K, Numata-Watanabe K, Hayasaka S. Methicillin-resistant staphylococci and ofloxacin-resistant bacteria from clinically healthy conjunctivas. Ophthalmic Res. 2001;33:136-139.
11. Drlica K. A strategy for fighting antibiotic resistance. ASM News. 2001; 67:27-33.
12. Courvalin P, Depardieu F. The influence of antibacterial mechanisms of action on the emergence, dissemination, and prevention of resistance. Ochsner Clin Symp Resist Use Misuse Antimicrob. 2000;(suppl):15-22.
13. Mather R, Karenchak LM, Romanowski EG, et al. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.
14. Stroman DW, Clark L, Macke L, et al. Moxifloxcain activity against quinolone resistance staphylococcal ocular isolates. Invest Ophthalmol Vis Sci. 2001;42:S255.
15. Olson RJ. Reducing the risk of postoperative endophthalmitis. Surv Ophthalmol. 2004;49:S55-S61.
16. Callegan MC, Englebert M, Parke DW 2nd. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev. 2002;15:111-124.
17. Sherwood DR, Rich WJ, Jacob JS. Bacterial contamination of intraocular and extraocular fluids during extracapsular cataract extraction. Eye. 1989; 3:308-312.
18. Speaker MG, Menikoff J. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 1991;98:1769-1775.
19. Taban M, Rao B, Reznik J, et al. Dynamic morphology of sutureless cataract wounds-effect of incision angle and location. Surv Ophthalmol. 2004;49:S62-S72.
20. Tipperman R. Pharmacologic considerations for cataract surgery. Curr Opin Ophthalmol. 2004;15:51-55.
21. Garcia-Saenz MC, Arias-Puente A, Fresnadillo-Martinez MJ, et al. Human aqueous humor levels of oral ciproploxacin, levofloxacin, and moxifloxacin. J Cataract Refract Surg. 2001;27:1969-1974.
22. Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Ophthalmol. 2003;121: 345-350.
23. Hwang DG. Fluoroquinolones resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol. 2004;49:S79-S83.
24. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, eiprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-505.